BACKGROUND: The clinical course of idiopathic pulmonary fibrosis (IPF) is characterized by progressive decline in lung function and eventual mortality. We sought to determine if future declines in pulmonary function, mortality, or both can be predicted from prior trends in pulmonary function tests (PFTs). METHODS: Data from 1981 to 2008 on 4,431 PFTs and mortality were analyzed from 734 subjects with IPF. The Kaplan-Meier method was used for mortality analyses. Mixed models were used to describe longitudinal pulmonary function dynamics, since PFTs were observed at varying time points from baseline. RESULTS: During the first year of follow-up, 135 subjects (73%) had stable FVC while 50 subjects (37%) showed a decline in FVC. During months 12 to 24 (1-2 years after diagnosis), a stable FVC occurred with the same frequency among both subjects whose FVC had declined during year 1 and whose FVC had remained stable (84.0% and 80.7%, respectively; P=.59). Among subjects alive at the end of year 1, those with a stable FVC were more likely to be alive at the end of year 2 than those whose FVC declined (hazard ratio [HR], 0.91 [95% CI, 0.87-0.94] and HR, 0.71 [95% CI, 0.62-0.78], respectively). CONCLUSIONS: PFT decline predicts early mortality, but not future declines in physiology, regardless of time since diagnosis.
BACKGROUND: The clinical course of idiopathic pulmonary fibrosis (IPF) is characterized by progressive decline in lung function and eventual mortality. We sought to determine if future declines in pulmonary function, mortality, or both can be predicted from prior trends in pulmonary function tests (PFTs). METHODS: Data from 1981 to 2008 on 4,431 PFTs and mortality were analyzed from 734 subjects with IPF. The Kaplan-Meier method was used for mortality analyses. Mixed models were used to describe longitudinal pulmonary function dynamics, since PFTs were observed at varying time points from baseline. RESULTS: During the first year of follow-up, 135 subjects (73%) had stable FVC while 50 subjects (37%) showed a decline in FVC. During months 12 to 24 (1-2 years after diagnosis), a stable FVC occurred with the same frequency among both subjects whose FVC had declined during year 1 and whose FVC had remained stable (84.0% and 80.7%, respectively; P=.59). Among subjects alive at the end of year 1, those with a stable FVC were more likely to be alive at the end of year 2 than those whose FVC declined (hazard ratio [HR], 0.91 [95% CI, 0.87-0.94] and HR, 0.71 [95% CI, 0.62-0.78], respectively). CONCLUSIONS: PFT decline predicts early mortality, but not future declines in physiology, regardless of time since diagnosis.
Authors: Talmadge E King; Sharon Safrin; Karen M Starko; Kevin K Brown; Paul W Noble; Ganesh Raghu; David A Schwartz Journal: Chest Date: 2005-01 Impact factor: 9.410
Authors: K R Flaherty; G B Toews; W D Travis; T V Colby; E A Kazerooni; B H Gross; A Jain; R L Strawderman; R Paine; A Flint; J P Lynch; F J Martinez Journal: Eur Respir J Date: 2002-02 Impact factor: 16.671
Authors: Yangjin Jegal; Dong Soon Kim; Tae Sun Shim; Chae-Man Lim; Sang Do Lee; Younsuck Koh; Woo Sung Kim; Won Dong Kim; Jin Seong Lee; William D Travis; Masanori Kitaichi; Thomas V Colby Journal: Am J Respir Crit Care Med Date: 2005-01-07 Impact factor: 21.405
Authors: Vibha N Lama; Kevin R Flaherty; Galen B Toews; Thomas V Colby; William D Travis; Qi Long; Susan Murray; Ella A Kazerooni; Barry H Gross; Joseph P Lynch; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2003-08-13 Impact factor: 21.405
Authors: Kevin R Flaherty; Jeanette A Mumford; Susan Murray; Ella A Kazerooni; Barry H Gross; Thomas V Colby; William D Travis; Andrew Flint; Galen B Toews; Joseph P Lynch; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2003-05-28 Impact factor: 21.405
Authors: K R Flaherty; E L Thwaite; E A Kazerooni; B H Gross; G B Toews; T V Colby; W D Travis; J A Mumford; S Murray; A Flint; J P Lynch; F J Martinez Journal: Thorax Date: 2003-02 Impact factor: 9.139
Authors: Ganesh Raghu; Kevin K Brown; Williamson Z Bradford; Karen Starko; Paul W Noble; David A Schwartz; Talmadge E King Journal: N Engl J Med Date: 2004-01-08 Impact factor: 91.245
Authors: Panagiota I Latsi; Roland M du Bois; Andrew G Nicholson; Thomas V Colby; Danai Bisirtzoglou; Ageliki Nikolakopoulou; Srihari Veeraraghavan; David M Hansell; Athol U Wells Journal: Am J Respir Crit Care Med Date: 2003-06-05 Impact factor: 21.405
Authors: L Ten Klooster; C H M van Moorsel; J M Kwakkel-van Erp; H van Velzen-Blad; J C Grutters Journal: Clin Exp Immunol Date: 2015-06-08 Impact factor: 4.330
Authors: Aaron Trimble; Bernadette R Gochuico; Thomas C Markello; Roxanne Fischer; William A Gahl; Jae K Lee; Youngchul Kim; Marie D Burdick; Robert M Strieter; Borna Mehrad Journal: Am J Respir Crit Care Med Date: 2014-12-15 Impact factor: 21.405
Authors: Margaret L Salisbury; Meng Xia; Yueren Zhou; Susan Murray; Nabihah Tayob; Kevin K Brown; Athol U Wells; Shelley L Schmidt; Fernando J Martinez; Kevin R Flaherty Journal: Chest Date: 2016-01-12 Impact factor: 9.410
Authors: Margaret L Salisbury; David A Lynch; Edwin J R van Beek; Ella A Kazerooni; Junfeng Guo; Meng Xia; Susan Murray; Kevin J Anstrom; Eric Yow; Fernando J Martinez; Eric A Hoffman; Kevin R Flaherty Journal: Am J Respir Crit Care Med Date: 2017-04-01 Impact factor: 21.405
Authors: Justin M Oldham; Shwu-Fan Ma; Fernando J Martinez; Kevin J Anstrom; Ganesh Raghu; David A Schwartz; Eleanor Valenzi; Leah Witt; Cathryn Lee; Rekha Vij; Yong Huang; Mary E Strek; Imre Noth Journal: Am J Respir Crit Care Med Date: 2015-12-15 Impact factor: 21.405
Authors: Brett Ley; Williamson Z Bradford; Eric Vittinghoff; Derek Weycker; Roland M du Bois; Harold R Collard Journal: Am J Respir Crit Care Med Date: 2016-09-15 Impact factor: 21.405